Ehave, Inc. Announces Plans to Launch A Series of Studies to Determine the Cause and Possible Cure for Hallucinogen-Persisting Perception Disorder
July 29, 2021 at 06:00 pm IST
Share
Ehave, Inc. announced plans to launch a series of studies to determine the cause and possible cure for hallucinogen-persisting perception disorder (HPPD). Hallucinogen-persisting perception disorder, or HPPD, can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. Ehave believes the key to widespread acceptance for psychedelics is a focus on the good as well as the bad, which is why are investing in this series of studies on HPPD. Individuals with HPPD have recurring visual disturbances that only recall the part of the drug trip that involved visions. The way these flashbacks in HPPD affect a person’s vision can be frustrating and may cause anxiety. Scientists and researchers do not know exactly how or why these negative results occur, but they are still working on the question. Some people have different flashback experience. Instead of a pleasurable trip, they experience confusing visual effects, such as halos around objects, distorted sizes or colors, and bright lights that won’t fade. People experiencing these disturbances may be entirely aware of everything else that’s happening. The interruption in field of vision can be annoying, disturbing, and possibly debilitating. That’s why these symptoms may be unsettling or upsetting. If these visual disturbances occur frequently, may have a condition called hallucinogen persisting perception disorder (HPPD). As many as 5% of LSD users report some version of HPPD and serious cases could be as frequent as 1 in every 100 users of psychedelics. HPPD is most commonly caused by LSD and Mushrooms, but also can be caused by MDMA, Cannabis, and even SSRIs. The market for an HPPD cure extends far beyond simple psychedelics. There have been various individual studies of the condition, but the Ehave study could be the largest patient study to date. Unlocking the genetic link will help point us towards treatment and a cure. The “Perception Restoration Foundation” a non-profit working on HPPD, will be releasing an in-depth documentary in the coming months to get the word out on the condition.
Ehave, Inc. is a Canada-based company, which is an engaged in the digital therapeutics delivering evidence-based therapeutic interventions to patients. The Companyâs primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. The Companyâs main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make decisions through data insights. The Companyâs Ehave Infinity Portal offers a machine learning and artificial intelligence platform with a growing set of tools and applications developed by the Company and its partners. This enables patients, healthcare providers and payers to address a range of conditions through data-driven involvement with the tools.